Application of Continuous Care Pattern Based on Information-Motivation-Behavioral Skills Model in out-of-Hospital Rehabilitation of Diabetic Foot Ulceration Patients: A Randomized Controlled Trial.

Int J Low Extrem WoundsAug 23, 2024 (epub)
Clinical ResearchEndocrinology

Zhenxue Zhao, Wenchao Xu, Suxia Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective randomized controlled trial evaluated information-motivation-behavioral skills (IMB)-based continuing care after hospital discharge in 88 patients with diabetic foot ulceration. Forty-four patients received routine care plus IMB-based continuing care, while 44 received routine care alone. Compared with control, the study group had significantly better blood glucose indicators at week 1, more patients without infection at weeks 1 and 3, more cured patients at week 3, and larger ulcer-healing areas at weeks 1 and 3 (all reported as P < .05).

Key findings

  • At week 1, FBS, PBG (2 h) and HbA1c were significantly lower in the IMB-based continuing-care group than in controls (P < .05).
  • The study group had significantly more non-infected patients at weeks 1 and 3 than the control group (P < .05).
  • At week 3, significantly more patients were cured in the study group; ulcer-healing area was also significantly larger at weeks 1 and 3 (P < .05).
  • Blood glucose indicators improved from week 1 to weeks 3 and 6 in both groups (P < .05).

Why it matters

Diabetic foot ulceration requires ongoing wound and metabolic management beyond hospital care. This trial suggests that structured continuing care incorporating information, motivation and behavioral skills may improve short-term glycemic measures and wound-related outcomes compared with routine care alone. The findings support further consideration of organized post-discharge support, while the reported results do not establish longer-term benefit.

What to keep in mind

The abstract reports outcomes only through week 6 and provides no effect sizes, limiting assessment of the magnitude and durability of benefit.

Source

Published in Int J Low Extrem Wounds. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.